Christine Blank

Seniors prescribed multiple courses of antibiotics were at greater risk for IBD.

Burnout, COVID-19 vaccines, and increased demands have come together to create the perfect storm of labor shortages within the industry.

Study finds higher Ischemic events and mortality in transcatheter valve replacement patients taking non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists.

Low-risk atrial fibrillation patients who take oral anticoagulants have a lower risk of dementia than those who do not, a study says.

The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.

Overestimating the bleeding risk of anticoagulants may lead to poor compliance.

Bleeding in patients with nonvalvular atrial fibrillation and coronary syndrome was reduced by apixaban versus vitamin K antagonists.

Many kidney disease patients with atrial fibrillation are not treated with anticoagulation, increasing their risk of stroke.

Study finds different anticoagulation treatment levels for patients with cognitive problems.

A meta-analysis of 95 studies indicates lower risk of stroke and intracranial hemorrhage.

Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.

The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.

The FDA has approved the first new treatment for flu in decades. Here's how it will impact sales of Tamiflu and vaccination rates. 

ISMP reports that some patients have inadvertently taken double doses of rivaroxaban in dosing mixups.

There is finally relief from “gag clauses,” which prevented pharmacists from telling patients they can pay a lower out-of-pocket cost for certain prescriptions than the copay with their health insurance.

A study found that treating patients with rivaroxaban for 45 days after hospital discharge reducedthe rate of nonfatal blood clots, but had no effect on fatal blood clots. 

A massive retrospective study compared several non-vitamin K antagonist oral anticoagulants (NOACs) to warfarin.

What do pharmacies have to do with the recent Surgeon General Advisory? A lot, actually.

A study found that apixaban is a safe alternative to VKAs for ablation of atrial fibrillation.

If the past few weeks are any indication, pharmacy isn’t going to be the same for very long.

Andaxanet alfa has shown effectiveness for patients needing hemostasis.

Easy-to-swallow news and studies for the busy pharmacist.

Zinbryta was taken off the market, leaving many patients with poor options.

Amazon quietly rolled out a line of OTC products-and that should scare you.

An independent pharmacy opted to settle a wrongful death lawsuit involving an opioid prescription.

In an effort to combat opioids, the FDA is pushing blister packs-something pharmacy groups have been advocating for.

Three medical groups have issued guidelines for the use of anticoagulants during cardiac surgery.

The DOAC edoxaban can replace dalteparin for treating cancer patients with venous thromboembolism.